Drug General Information (ID: DDITQPSDCB)
Drug Name			Pegaptanib (ophthalmic)		Drug Info		Pegloticase		Drug Info
Drug Type		Aptamer				Protein/peptide
Therapeutic Class		Antiangiogenic Agents				Antihyperuricemic Agents

Mechanism of Pegaptanib (ophthalmic)-Pegloticase Interaction (Severity Level: Moderate)
Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Pegaptanib (ophthalmic)				Pegloticase
Mechanism		Reduces pharmacological effects of pegloticase				Pegloticase
Key Mechanism Factor 1
		Factor Name		Pharmacodynamics
		Factor Description		Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure.
Mechanism Description		Attenuated pharmacological effects of  Pegloticase when combined with Pegaptanib (ophthalmic)

Recommended Action
Management		Clinicians should be aware of the potential for diminished effects of other pegylated agents following treatment with pegloticase.

References
1	Product Information. Krystexxa (pegloticase). Savient Pharmaceuticals, East Brunswick, NJ.